Vera Therapeutics (VERA) Accumulated Expenses (2020 - 2026)

Vera Therapeutics (VERA) has 7 years of Accumulated Expenses data on file, last reported at $31.2 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 173.05% year-over-year to $31.2 million; the trailing twelve-month figure through Mar 2026 stood at $31.2 million (up 173.05% YoY), and the FY2025 full-year result was $18.7 million, up 15.27% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $31.2 million, up from $18.7 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $31.2 million in Q1 2026 and bottomed at $1.1 million in Q1 2023.
• The 5-year median for Accumulated Expenses is $10.2 million (2022), against an average of $11.1 million.
• The widest annual swing landed in 2023, when Accumulated Expenses slumped 88.79%; it then soared 793.83% in 2025.
• A 5-year view of Accumulated Expenses shows it stood at $11.0 million in 2022, then tumbled by 64.14% to $3.9 million in 2023, then soared by 312.59% to $16.2 million in 2024, then advanced by 15.27% to $18.7 million in 2025, then jumped by 67.06% to $31.2 million in 2026.
• The last three Accumulated Expenses figures came in at $31.2 million (Q1 2026), $18.7 million (Q4 2025), and $23.5 million (Q3 2025), per Business Quant data.

Peer Comparison